Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,855 across all filing types
Latest filing 2025-08-07 Report Publication Anno…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
1. Subscription Right Plan 2025 (B)_Board Report_7_180-7_191_ENG_FINAL_Website(inclplan)(2039027.1).pdf
Report Publication Announcement Classification · 99% confidence The document is a formal 'Report of the Board of Directors' regarding the issuance of subscription rights (stock options) and the cancellation of preferential subscription rights for shareholders. It details the legal basis (Belgian Code of Companies and Associations), the purpose of the plan, the impact on authorized capital, and the justification for the dilution of existing shares. This type of document is a standard corporate governance and capital structure disclosure, which falls under the category of Share Issue/Capital Change (SHA) as it pertains to the issuance of new equity-linked instruments.
2025-08-07 English
1. Subscription Right Plan 2025 (B)_Board Report_7_180-7_191_NL_FINAL_Website(inclplan)(2039028.1).pdf
Management Reports Classification · 95% confidence The document is a formal report from the Board of Directors of Galapagos NV, prepared in accordance with the Belgian Code of Companies and Associations (WVV). It details a proposal to issue subscription rights (stock options) to employees and management, including the justification for the cancellation of shareholder pre-emptive rights. This type of document is a standard corporate governance and capital structure disclosure, specifically related to share-based compensation plans. It is not an annual report, earnings release, or simple announcement, but rather a detailed management report regarding capital changes and remuneration policy. Therefore, it is best classified as a Management Report (MDA).
2025-08-07 Dutch
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Regulatory Filings Classification · 100% confidence The document is a press release from Galapagos NV announcing that the FDA has granted RMAT (Regenerative Medicine Advanced Therapy) status to their drug candidate GLPG5101. It follows the standard format of a corporate press release, including a headline, dateline, summary of the regulatory news, background on the drug and clinical trials, and standard legal disclaimers regarding forward-looking statements. Since this is a general regulatory announcement regarding company operations and drug development status that does not fit into specific categories like financial results (ER/IR), dividends (DIV), or share transactions (POS), it is classified as a general regulatory filing.
2025-08-06 Dutch
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Regulatory Filings Classification · 95% confidence The document is a press release issued by Galapagos NV announcing that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to one of its product candidates, GLPG5101. It details the clinical context, the benefits of the designation, and provides background on the study and the company. As this is a corporate announcement regarding regulatory status and clinical development progress that does not fit into specific financial reporting categories like 10-K, IR, or ER, it is classified as a general regulatory filing.
2025-08-06 English
Galapagos Press Release_RMAT Designation_GLPG5101_ENG_final.pdf
Regulatory Filings Classification · 95% confidence The document is a press release issued by Galapagos NV announcing that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to one of its product candidates, GLPG5101. It details the clinical context, the benefits of the designation, and provides background on the study and the company. As this is a corporate announcement regarding regulatory status and clinical development progress that does not fit into specific financial reporting categories like 10-K, IR, or ER, it is classified as a general regulatory filing.
2025-08-06 English
Galapagos Press Release_RMAT Designation_GLPG5101_NLfinal.pdf
Regulatory Filings Classification · 100% confidence The document is a press release issued by Galapagos NV announcing that the FDA has granted 'Regenerative Medicine Advanced Therapy' (RMAT) status to their drug candidate GLPG5101. It follows the standard format of a corporate press release, including a headline, dateline, company boilerplate, and forward-looking statements disclaimer. Since it is a general regulatory announcement regarding company operations and product development that does not fit into specific categories like financial reports, earnings calls, or shareholder voting, it is classified as a Regulatory Filing (RNS).
2025-08-06 Dutch

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.